A. K. Abbas and A. H. Lichtman, Cellular and molecular immunology, vol.31, p.58, 2010.

M. Abe, K. Okada, K. Hayashida, F. Matsuo, K. Shiosaki et al., Duration of neutralizing antibody titer after Japanese encephalitis vaccination, Microbiology and immunology, vol.51, issue.6, p.60, 2007.

V. Abedi, P. Lu, R. Hontecillas, M. Verma, G. Vess et al., Phase III placebo-controlled, randomized clinical trial with synthetic Crohn's disease patients to evaluate treatment response. Computational Modeling-Based Discovery of Novel Classes of Anti-Inflammatory Drugs that Target Lanthionine Synthetase C-Like Protein, Emerging Trends in Computational Biology, vol.2, p.169, 2015.

N. M. Adams, T. E. O'sullivan, C. D. Geary, J. M. Karo, R. A. Amezquita et al., NK cell responses redefine immunological memory, The Journal of Immunology, vol.197, issue.8, p.100, 2016.

S. T. Agnandji, A. Huttner, M. E. Zinser, P. Njuguna, C. Dahlke et al., Phase 1 trials of rVSV Ebola vaccine in Africa and Europe, New England Journal of Medicine, vol.374, issue.17, p.55, 2016.

R. Ahmed and D. Gray, Immunological memory and protective immunity: understanding their relation, Science, vol.272, issue.5258, p.36, 1996.

I. J. Amanna and M. K. Slifka, Mechanisms that determine plasma cell lifespan and the duration of humoral immunity, Immunological reviews, vol.236, issue.1, p.63, 2010.

I. J. Amanna, N. E. Carlson, and S. M. , Duration of humoral immunity to common viral and vaccine antigens, New England Journal of Medicine, vol.357, issue.19, p.60, 2007.

M. Andraud, O. Lejeune, J. Z. Musoro, B. Ogunjimi, P. Beutels et al., Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis A virus, PLOS Computational Biology, vol.8, issue.3, p.63, 2012.

R. Antia, C. T. Bergstrom, S. S. Pilyugin, S. M. Kaech, and A. R. , Models of CD8+ responses: 1. What is the antigen-independent proliferation program, Journal of Theoretical Biology, vol.221, issue.4, p.62, 2003.

R. Antia, V. V. Ganusov, and A. R. , The role of models in understanding CD8+ T-cell memory, Nature Reviews Immunology, vol.5, issue.2, p.44, 2005.

B. Autran, G. Carcelain, T. S. Li, C. Blanc, D. Mathez et al., Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease, Science, vol.277, issue.5322, p.108, 1997.

L. R. Baden, E. Karita, G. Mutua, L. Bekker, G. Gray et al., Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial, Annals of Internal Medicine, vol.164, issue.5, p.42, 2016.

F. Bailleux, L. Coudeville, A. Kolenc-saban, J. Bevilacqua, and L. Barreto, Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data, Vaccine, vol.26, issue.31, p.60, 2008.

S. Baize, D. Pannetier, L. Oestereich, T. Rieger, L. Koivogui et al., Emergence of Zaire Ebola virus disease in Guinea, New England Journal of Medicine, vol.371, issue.15, p.49, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01011799

D. H. Barouch, A step forward for HIV vaccines, The Lancet HIV, vol.5, issue.7, p.39, 2018.

M. Battegay, R. Nüesch, B. Hirschel, and G. R. Kaufmann, Immunological recovery and antiretroviral therapy in HIV-1 infection. The Lancet Infectious Diseases, vol.6, p.108, 2006.

N. Bäuerle and U. Rieder, Markov decision processes with applications to finance, p.162, 2011.

S. L. Beal, L. B. Sheiner, A. Boeckmann, and R. J. Bauer, NONMEM users guides

P. Bejon, E. Ogada, T. Mwangi, P. Milligan, T. Lang et al., Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya, PLOS ONE, vol.2, issue.8, p.38, 2007.

L. Bekker, Z. Moodie, N. Grunenberg, F. Laher, G. D. Tomaras et al., Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, p.39, 2018.

R. Bellman, Dynamic programming, p.117, 1957.

A. Bensoussan, Lectures on stochastic control, Nonlinear filtering and stochastic control, p.121, 1982.

S. Beq, J. Delfraissy, and T. J. , Interleukin-7 (IL-7): immune function, involvement in the pathogenesis of HIV infection and therapeutic potential, European Cytokine Network, vol.15, issue.4, p.110, 2004.

S. A. Berkman, M. L. Lee, and G. R. , Clinical uses of intravenous immunoglobulins, Annals of Internal Medicine, vol.112, issue.4, p.58, 1990.

E. R. Berndt, B. H. Hall, R. E. Hall, and H. J. , Estimation and inference in nonlinear structural models, Annals of Economic and Social Measurement, vol.3, issue.4, p.69, 1974.

W. F. Bierman, M. A. Van-agtmael, M. Nijhuis, S. A. Danner, and C. A. Boucher, HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review, AIDS, vol.23, issue.3, p.108, 2009.

G. F. Black, R. E. Weir, S. Floyd, L. Bliss, D. K. Warndorff et al., BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies, The Lancet, vol.359, issue.9315, p.42, 2002.

A. Bobrowski, T. Lipniacki, and K. Pichór, Asymptotic behavior of distributions of mRNA and protein levels in a model of stochastic gene expression, Journal of mathematical analysis and applications, vol.333, issue.2, p.121, 2007.

P. Bokes, J. R. King, and A. T. Wood, Transcriptional bursting diversifies the behaviour of a toggle switch: hybrid simulation of stochastic gene expression, Bulletin of Mathematical Biology, vol.75, issue.2, pp.351-371, 2013.

E. Bonabeau, Agent-based modeling: Methods and techniques for simulating human systems, Proceedings of the National Academy of Sciences, vol.99, issue.3, p.43, 2002.

V. Bouteloup, C. Sabin, A. Mocroft, L. Gras, N. Pantazis et al., Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients, HIV Medicine, vol.18, issue.1, p.109, 2017.

P. Bovier, J. Bock, L. Loutan, T. Farinelli, R. Glueck et al., Long-term immunogenicity of an inactivated virosome hepatitis A vaccine, Journal of Medical Virology, vol.68, issue.4, p.60, 2002.

O. H. Brekke and I. Sandlie, Therapeutic antibodies for human diseases at the dawn of the twenty-first century, Nature Reviews Drug Discovery, vol.2, issue.1, pp.52-62, 2003.

M. W. Brinkhof, O. Mayorga, J. Bock, U. Heininger, and C. Herzog, Kinetics of maternally acquired anti-hepatitis A antibodies: prediction of waning based on maternal or cord blood antibody levels, Vaccine, vol.31, issue.11, p.58, 2013.

M. Brisson, É. Bénard, M. Drolet, J. A. Bogaards, I. Baussano et al., Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models, The Lancet Public Health, vol.1, issue.1, p.38, 2016.

S. P. Buchbinder, D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg et al., Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-ofconcept trial, The Lancet, vol.372, issue.9653, p.42, 2008.

E. Buckwar and M. G. Riedler, An exact stochastic hybrid model of excitable membranes including spatio-temporal evolution, Journal of Mathematical Biology, vol.63, issue.6, p.121, 2011.

D. Butler, What first case of sexually transmitted Ebola means for public health, Nature News, p.49, 2015.

R. E. Callard and A. J. Yates, Immunology and mathematics: crossing the divide, Immunology, vol.115, issue.1, p.44, 2005.

B. Callendret, J. Vellinga, K. Wunderlich, A. Rodriguez, R. Steigerwald et al., A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates, PLOS ONE, vol.13, issue.2, p.56, 2018.

J. F. Camargo, H. Kulkarni, B. K. Agan, A. A. Gaitan, L. A. Beachy et al.,

, Is Associated with Higher CD4+ T Cell Counts in HIV-1-Positive Individuals with Highly Active Antiretroviral Therapy-Induced Viral Load Suppression, The Journal of Infectious Diseases, vol.199, issue.12, p.110, 2009.

M. R. Capeding, N. H. Tran, S. R. Hadinegoro, H. I. Ismail, T. Chotpitayasunondh et al., The Lancet, vol.384, issue.9951, p.41, 2014.

A. Cappuccio, F. Castiglione, and P. B. , Determination of the optimal therapeutic protocols in cancer immunotherapy, Mathematical Biosciences, vol.209, issue.1, p.118, 2007.

F. Castiglione and B. Piccoli, Cancer immunotherapy, mathematical modeling and optimal control, Journal of Theoretical Biology, vol.247, issue.4, p.118, 2007.

F. Castiglione and B. Piccoli, Optimal control in a model of dendritic cell transfection cancer immunotherapy, Bulletin of Mathematical Biology, vol.68, issue.2, p.118, 2006.

N. M. Dixit and A. S. Perelson, HIV dynamics with multiple infections of target cells, Proceedings of the National Academy of Sciences, vol.102, issue.23, p.65, 2005.

J. Drylewicz and D. Commenges, Maximum a posteriori estimation in dynamical models of primary HIV infection, Statistical Communications in Infectious Diseases, vol.4, issue.1

J. Dunning, S. B. Kennedy, A. Antierens, J. Whitehead, I. Ciglenecki et al., Experimental treatment of Ebola virus disease with brincidofovir, PLOS ONE, vol.11, issue.9, p.51, 2016.

J. Dunning, F. Sahr, A. Rojek, F. Gannon, G. Carson et al., Experimental treatment of Ebola virus disease with TKM130803: a single-arm phase 2 clinical trial, PLOS Medicine, vol.13, issue.4, p.51, 2016.

S. Duwal, S. Winkelmann, C. Schütte, V. Kleist, and M. , Optimal treatment strategies in the context of 'treatment for prevention'against HIV-1 in resource-poor settings, PLOS Computational Biology, vol.11, issue.4, p.119, 2015.

R. Eftimie, J. J. Gillard, and D. A. Cantrell, Mathematical models for immunology: Current state of the art and future research directions, Bulletin of Mathematical Biology, vol.78, issue.10, p.119, 2016.

, Eurosurveillance editorial team. First innovative medicines initiative ebola projects launched, Eurosurveillance, vol.20, issue.3, p.52, 2015.

K. Ewer, T. Rampling, N. Venkatraman, G. Bowyer, D. Wright et al., A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA, New England Journal of Medicine, vol.374, issue.17, p.54, 2016.

D. L. Farber, M. G. Netea, A. Radbruch, K. Rajewsky, and R. M. , Immunological memory: lessons from the past and a look to the future, Nature Reviews Immunology, vol.16, issue.2, p.36, 2016.

R. B. Ferreira, L. C. Antunes, and F. B. , Should the human microbiome be considered when developing vaccines?, PLOS Pathogens, vol.6, issue.11, p.42, 2010.

K. Fink, Origin and function of circulating plasmablasts during acute viral infections, Frontiers in Immunology, vol.3, p.58, 2012.

M. A. Fischl, D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding et al., The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex, New England Journal of Medicine, vol.317, issue.4, p.108, 1987.

E. N. Fish, The X-files in immunity: sex-based differences predispose immune responses, Nature Reviews Immunology, vol.8, issue.9, p.41, 2008.

V. A. Folcik, G. C. An, and C. G. Orosz, The Basic Immune Simulator: an agent-based model to study the interactions between innate and adaptive immunity, Theoretical Biology and Medical Modelling, vol.4, issue.1, p.43, 2007.

N. C. Framstad, B. Øksendal, and A. Sulem, Sufficient stochastic maximum principle for the optimal control of jump diffusions and applications to finance, Journal of Optimization Theory and Applications, vol.121, issue.1, p.121, 2004.

C. Fraser, J. E. Tomassini, L. Xi, G. Golm, M. Watson et al., Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine, Vaccine, vol.25, issue.21, p.61, 2007.

K. A. Fraser, J. M. Schenkel, S. C. Jameson, and V. Vezys, Preexisting high frequencies of memory CD8+ T cells favor rapid memory differentiation and preservation of proliferative potential upon boosting, Immunity, vol.39, issue.1, p.36, 2013.

D. Bibliography-frölich, C. Giesecke, H. E. Mei, K. Reiter, C. Daridon et al., Secondary immunization generates clonally related antigen-specific plasma cells and memory B cells, The Journal of Immunology, vol.185, issue.5, p.58, 2010.

A. Gelman, D. Lee, and G. J. Stan, A probabilistic programming language for Bayesian inference and optimization, Journal of Educational and Behavioral Statistics, vol.40, issue.5, p.70, 2015.

R. N. Germain, The art of the probable: system control in the adaptive immune system, Science, vol.293, issue.5528, p.43, 2001.

R. N. Germain, Vaccines and the future of human immunology, Immunity, vol.33, issue.4, p.99, 2010.

R. N. Germain, Will Systems Biology Deliver Its Promise and Contribute to the Development of New or Improved Vaccines? What Really Constitutes the Study of "Systems Biology" and How Might Such an Approach Facilitate Vaccine Design. Cold Spring Harbor perspectives in biology, vol.43, p.99, 2017.

H. Golding, S. Khurana, and M. Zaitseva, What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection. Cold Spring Harbor perspectives in biology, vol.10, p.56, 2018.

C. E. Gómez, J. L. Nájera, B. Perdiguero, J. García-arriaza, C. O. Sorzano et al., The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional and selective effector memory T cell responses to HIV-1 antigens, Journal of Virology, p.38, 2011.

C. Gong, J. J. Linderman, and D. Kirschner, Harnessing the heterogeneity of T cell differentiation fate to fine-tune generation of effector and memory T cells, Frontiers in Immunology, vol.5, p.45, 2014.

N. C. Grassly, I. Praharaj, S. Babji, S. P. Kaliappan, S. Giri et al., The effect of azithromycin on the immunogenicity of oral poliovirus vaccine: a double-blind randomised placebo-controlled trial in seronegative Indian infants, The Lancet Infectious Diseases, vol.16, issue.8, p.42, 2016.

F. Graw, K. S. Weber, P. M. Allen, and A. S. Perelson, Dynamics of CD4+ T cell responses against Listeria monocytogenes, The Journal of Immunology, vol.189, issue.11, p.44, 2012.

L. Gross, E. Lhomme, C. Pasin, L. Richert, and T. R. , Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination, International Journal of Infectious Diseases, vol.74, p.57, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01888913

J. Guedj and R. Thiébaut, Maximum likelihood estimation in dynamical models of HIV, Biometrics, vol.63, issue.4, p.67, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00204269

J. Guedj and R. Thiébaut, Practical identifiability of HIV dynamics models, Bulletin of Mathematical Biology, vol.69, issue.8, p.70, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00204273

J. Guedj, G. Piorkowski, F. Jacquot, V. Madelain, T. H. Nguyen et al., Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques, PLOS Medicine, vol.15, issue.3, p.51, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02178005

M. Gurwith, M. Lock, E. M. Taylor, G. Ishioka, J. Alexander et al., Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebocontrolled, phase 1 study. The Lancet Infectious Diseases, vol.13, p.38, 2013.

T. Hagan and B. Pulendran, Will systems biology deliver its promise and contribute to the development of new or improved vaccines? From data to understanding through systems biology. Cold Spring Harbor perspectives in biology, p.103, 2017.

T. Hagan, H. I. Nakaya, and S. Subramaniam, Systems vaccinology: enabling rational vaccine design with systems biological approaches, Vaccine, vol.33, issue.40, p.99, 2015.

E. Hammarlund, A. Thomas, I. J. Amanna, L. A. Holden, O. D. Slayden et al., Plasma cell survival in the absence of B cell memory, Nature Communications, vol.8, issue.1, p.58, 2017.

S. M. Hammer, D. A. Katzenstein, M. D. Hughes, H. Gundacker, R. T. Schooley et al., A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter, New England Journal of Medicine, vol.335, issue.15, p.108, 1996.

S. M. Hammer, M. E. Sobieszczyk, H. Janes, S. T. Karuna, M. J. Mulligan et al., Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine, New England Journal of Medicine, vol.369, issue.22, p.38, 2013.

T. Hanke, A. J. Mcmichael, M. J. Dennis, S. A. Sharpe, L. A. Powell et al., Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice, Vaccine, vol.23, issue.12, p.98, 2005.

R. Haque, C. Snider, Y. Liu, J. Z. Ma, L. Liu et al., Oral polio vaccine response in breast fed infants with malnutrition and diarrhea, Vaccine, vol.32, issue.4, p.41, 2014.

M. Hecker, S. Lambeck, S. Toepfer, E. Van-someren, and G. R. , Gene regulatory network inference: data integration in dynamic models-a review, Biosystems, vol.96, issue.1, p.102, 2009.

A. M. Henao-restrepo, A. Camacho, I. M. Longini, C. H. Watson, W. J. Edmunds et al., Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial, Ebola Ça Suffit!). The Lancet, vol.389, p.55, 2017.

N. Hens, A. H. Ghebretinsae, K. Hardt, P. Van-damme, V. Herck et al., Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults, Vaccine, vol.32, issue.13, p.61, 2014.

D. G. Heppner, T. L. Kemp, B. K. Martin, W. J. Ramsey, R. Nichols et al., Safety and immunogenicity of the rVSV? G-ZEBOVGP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study, The Lancet Infectious Diseases, vol.17, issue.8, p.55, 2017.

U. Herbach, A. Bonnaffoux, T. Espinasse, and O. Gandrillon, Inferring gene regulatory networks from single-cell data: a mechanistic approach, BMC Systems Biology, vol.11, issue.1, p.165, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01646910

O. Hernández-lerma, Adaptive Markov control processes, Applied Mathematical Sciences, vol.79, p.162, 1989.

K. A. Huang, C. K. Li, -. Clutterbuck, E. Chui, C. Wilkinson et al., Virus-specific antibody secreting cell, memory B-cell, and sero-antibody responses in the human influenza challenge model, The Journal of Infectious Diseases, vol.209, issue.9, p.58, 2014.

A. Huttner, J. Dayer, S. Yerly, C. Combescure, F. Auderset et al., The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebocontrolled phase 1/2 trial. The Lancet Infectious Diseases, Immunological reviews, vol.15, issue.10, p.58, 2015.

A. S. Ishizuka, K. E. Lyke, A. Dezure, A. A. Berry, T. L. Richie et al., Protection against malaria at 1 year and immune correlates following PfSPZ vaccination, Nature Medicine, vol.22, issue.6, p.102, 2016.

E. Isolauri, J. Joensuu, H. Suomalainen, M. Luomala, and T. Vesikari, Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG, Vaccine, vol.13, issue.3, p.42, 1995.

C. A. Janeway, P. Travers, M. Walport, and M. Shlomchik, Immunobiology: the immune system in health and disease, vol.5, p.37, 2001.

A. Jarne, D. Commenges, L. Villain, M. Prague, Y. Lévy et al., Modeling CD4 + T cells dynamics in HIV-infected patients receiving repeated cycles of exogenous Interleukin 7, The Annals of Applied Statistics, vol.11, issue.3, p.161, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01579008

J. Munoz and A. , Modeling the effect of exogenous Interleukin 7 in HIV patients under antiretroviral therapy with low immune reconstitution, p.113, 2015.
URL : https://hal.archives-ouvertes.fr/tel-01273295

W. Jilg, M. Schmidt, F. Deinhardt, and Z. R. , Hepatitis B vaccination: how long does protection last? The Lancet, vol.324, p.58, 1984.

K. Johnson, P. Webb, J. Lange, and F. Murphy, Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire, The Lancet, p.47, 1977.

A. R. Joyce and B. Ø. Palsson, The model organism as a system: integrating 'omics' data sets, Nature Reviews Molecular Cell Biology, vol.7, issue.3, p.102, 2006.

B. Julg and B. D. Walker, The Paradox of Incomplete CD4+ Cell Count Restoration Despite Successful Antiretroviral Treatment and the Need to Start Highly Active Antiretroviral Therapy Early, Clinical Infectious Diseases, vol.48, issue.6, p.109, 2009.

R. E. Kass and D. Steffey, Approximate Bayesian inference in conditionally independent hierarchical models (parametric empirical Bayes models), Journal of the American Statistical Association, vol.84, issue.407, p.71, 1989.

C. F. Kelley, C. M. Kitchen, P. W. Hunt, B. Rodriguez, F. M. Hecht et al., Incomplete Peripheral CD4+ Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment, Clinical Infectious Diseases, vol.48, issue.6, p.109, 2009.

S. B. Kennedy, F. Bolay, M. Kieh, G. Grandits, M. Badio et al., Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia, New England Journal of Medicine, vol.377, issue.15, p.54, 2017.

R. Keshwara, R. F. Johnson, and M. J. Schnell, Toward an effective Ebola virus vaccine, Annual Review of Medicine, vol.68, p.51, 2017.

H. Kibuuka, N. M. Berkowitz, M. Millard, M. E. Enama, A. Tindikahwa et al., Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial, The Lancet, vol.385, issue.9977, p.52, 2015.

P. S. Kim, P. P. Lee, and L. D. , Modeling regulation mechanisms in the immune system, Journal of Theoretical Biology, vol.246, issue.1, p.44, 2007.

M. M. Kitahata, S. J. Gange, A. G. Abraham, B. Merriman, M. S. Saag et al., Effect of early versus deferred antiretroviral therapy for HIV on survival, New England Journal of Medicine, vol.360, issue.18, p.109, 2009.

B. Kohler, Mathematically modeling dynamics of T cell responses: predictions concerning the generation of memory cells, Journal of Theoretical Biology, vol.245, issue.4, p.181, 2007.

M. J. Kozal, K. Kroodsma, M. A. Winters, R. W. Shafer, B. Efron et al., Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy, Annals of Internal Medicine, vol.121, issue.4, p.108, 1994.

P. R. Krause, P. R. Bryant, T. Clark, W. Dempsey, E. Henchal et al., Immunology of protection from Ebola virus infection, Science translational medicine, vol.7, issue.286, p.56, 2015.

E. Kuhn and M. Lavielle, Maximum likelihood estimation in nonlinear mixed effects models, Computational Statistics & Data Analysis, vol.49, issue.4, p.73, 2005.

J. H. Kuhn, Y. Bao, S. Bavari, S. Becker, S. Bradfute et al., Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae, Archives of Virology, vol.158, issue.1, p.48, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00965887

M. K. Lalor, A. Ben-smith, P. Gorak-stolinska, R. E. Weir, S. Floyd et al., Population differences in immune responses to Bacille Calmette-Guerin vaccination in infancy, The Journal of Infectious Diseases, vol.199, issue.6, p.42, 2009.

T. Lambe, G. Bowyer, and K. J. Ewer, A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines? Phil, Trans. R. Soc. B, vol.372, p.51, 1721.

C. G. Lange and M. Lederman, Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection, Journal of Antimicrobial Chemotherapy, vol.51, issue.1, pp.1-4, 2003.

A. Lanzavecchia and F. Sallusto, Human B cell memory, Current Opinion in Immunology, vol.21, issue.3, p.58, 2009.

B. A. Larder, G. Darby, and D. D. Richman, HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy, Science, vol.243, issue.4899, p.108, 1989.

M. Lavielle and F. Mentré, Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software, Journal of Pharmacokinetics and Pharmacodynamics, vol.34, issue.2, p.163, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00156907

D. Le, J. D. Miller, and V. V. Ganusov, Mathematical modeling provides kinetic details of the human immune response to vaccination, Frontiers in Cellular and Infection Microbiology, vol.4, p.65, 2015.

J. Ledgerwood, P. Costner, N. Desai, L. Holman, M. Enama et al., A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults, Vaccine, vol.29, issue.2, p.54, 2010.

J. E. Ledgerwood, N. J. Sullivan, and G. B. , Chimpanzee Adenovirus Vector Ebola Vaccine-Preliminary Report, New England journal of medicine, vol.373, issue.8, p.54, 2015.

J. E. Ledgerwood, A. D. Dezure, D. A. Stanley, E. E. Coates, L. Novik et al., Chimpanzee adenovirus vector Ebola vaccine, New England Journal of Medicine, vol.376, issue.10, p.52, 2017.

H. Y. Lee, D. J. Topham, S. Y. Park, J. Hollenbaugh, J. Treanor et al., Simulation and prediction of the adaptive immune response to influenza A virus infection, Journal of Virology, vol.83, issue.14, p.44, 2009.

Y. Lee, M. Newport, T. Goetghebuer, C. Siegrist, H. Weiss et al., Influence of genetic and environmental factors on the immunogenicity of Hib vaccine in Gambian twins, Vaccine, vol.24, issue.25, p.41, 2006.

T. Leino, K. Auranen, P. Mäkelä, H. Käyhty, and A. Takala, Dynamics of natural immunity caused by subclinical infections, case study on Haemophilus influenzae type b (Hib), vol.125, p.60, 2000.

D. C. Lenz, S. K. Kurz, E. Lemmens, S. P. Schoenberger, J. Sprent et al., IL-7 regulates basal homeostatic proliferation of antiviral CD4+ T cell memory, Proceedings of the National Academy of Sciences, vol.101, issue.25, p.110, 2004.

A. Leone, M. Rohankhedkar, A. Okoye, A. Legasse, M. K. Axthelm et al., Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses, The Journal of Immunology, vol.185, issue.3, p.110, 2010.

E. Lesaffre and B. Spiessens, On the effect of the number of quadrature points in a logistic random-effects model: An example, Journal of the Royal Statistical Society. Series C, vol.50, p.67, 2001.

E. Leuridan, N. Hens, V. Hutse, M. Aerts, and P. Van-damme, Kinetics of maternal antibodies against rubella and varicella in infants, Vaccine, vol.29, issue.11, p.58, 2011.

Y. Levy, I. Sereti, G. Tambussi, J. Routy, J. Lelievre et al., Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study, Clinical Infectious Diseases, vol.55, issue.2, p.110, 2012.

Y. Levy, C. Lacabaratz, L. Weiss, J. Viard, C. Goujard et al., Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment, The Journal of Clinical Investigation, vol.119, issue.4, p.110, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00484803

Y. Lévy, C. Lane, P. Piot, A. H. Beavogui, M. Kieh et al., Prevention of Ebola virus disease through vaccination: where we are in 2018. The Lancet, p.53, 2018.

C. Lewden, G. Chêne, P. Morlat, F. Raffi, M. Dupon et al., HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.46, issue.1, p.109, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00170726

J. Li, L. Hou, F. Meng, S. Wu, Y. Hu et al., Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial, The Lancet Global Health, vol.5, issue.3, p.54, 2017.

G. Liu, G. Wong, S. Su, Y. Bi, F. Plummer et al., Clinical Evaluation of Ebola Virus Disease Therapeutics, Trends in Molecular Medicine, vol.23, issue.9, p.51, 2017.

W. B. Liu, Z. X. Li, Y. Du, and G. W. Cao, Ebola virus disease: from epidemiology to prophylaxis, Military Medical Research, vol.2, issue.1, p.49, 2015.

E. L. López, M. M. Contrini, A. Mistchenko, A. Kieffer, R. F. Baggaley et al., Modeling the long-term persistence of hepatitis A antibody after a two-dose vaccination schedule in Argentinean children, The Pediatric infectious disease journal, vol.34, issue.4, p.60, 2015.

T. A. Louis, Finding the observed information matrix when using the EM algorithm, Journal of the Royal Statistical Society. Series B (Methodological), p.67, 1982.

C. L. Mackall, T. J. Fry, C. Bare, P. Morgan, A. Galbraith et al., IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation, Blood, vol.97, issue.5, p.110, 2001.

M. K. Macleod, J. W. Kappler, and M. P. , Memory CD4 T cells: generation, reactivation and re-assignment, Immunology, vol.130, issue.1, p.36, 2010.

L. Magni, D. M. Raimondo, C. Dalla-man, G. De-nicolao, B. Kovatchev et al., Model predictive control of glucose concentration in type I diabetic patients: An in silico trial, Biomedical Signal Processing and Control, vol.4, issue.4, p.168, 2009.

C. A. Magwira and T. M. , Composition of gut microbiota and its influence on the immunogenicity of oral rotavirus vaccines. Vaccine, p.42, 2018.

D. Marbach, R. J. Prill, T. Schaffter, C. Mattiussi, D. Floreano et al., Revealing strengths and weaknesses of methods for gene network inference, Proceedings of the National Academy of Sciences, p.102, 2010.

D. W. Marquardt, An algorithm for least-squares estimation of nonlinear parameters, Journal of the society for Industrial and Applied Mathematics, vol.11, issue.2, p.69, 1963.

J. E. Martin, N. J. Sullivan, M. E. Enama, I. J. Gordon, M. Roederer et al., A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial, Clinical and vaccine immunology, vol.13, issue.11, p.52, 2006.

M. D. Martin and V. P. Badovinac, Influence of time and number of antigen encounters on memory CD8 T cell development, Immunologic research, vol.59, issue.1-3, p.36, 2014.

A. Marzi, S. J. Robertson, E. Haddock, F. Feldmann, P. W. Hanley et al., VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain, Science, vol.349, issue.6249, p.56, 2015.

T. C. Mast, L. Kierstead, S. B. Gupta, A. A. Nikas, E. G. Kallas et al., International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials, Vaccine, vol.28, issue.4, p.38, 2010.

W. G. Metzger and S. Vivas-martínez, Questionable efficacy of the rVSV-ZEBOV Ebola vaccine, The Lancet, vol.391, p.53, 2018.

I. D. Milligan, M. M. Gibani, R. Sewell, E. A. Clutterbuck, D. Campbell et al., Safety and immunogenicity of novel adenovirus type 26-and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial, JAMA, vol.315, issue.15, p.52, 2016.

D. C. Montefiori, B. Metch, M. J. Mcelrath, S. Self, K. J. Weinhold et al., Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines, The Journal of Infectious Diseases, vol.190, issue.11, p.41, 2004.

P. Morlat, Prise en charge médicale des personnes vivant avec le VIH. Recommandations du groupe d'experts, Sous la direction du Pr. Philippe Morlat et sous l'égide du CNS et de l'ANRS, p.108, 2017.

C. N. Morris, Parametric empirical Bayes inference: theory and applications, Journal of the American Statistical Association, vol.78, issue.381, p.71, 1983.

E. Muyanja, A. Ssemaganda, P. Ngauv, R. Cubas, H. Perrin et al., Immune activation alters cellular and humoral responses to yellow fever 17D vaccine, The Journal of Clinical Investigation, vol.124, issue.7, p.42, 2014.

H. I. Nakaya, J. Wrammert, E. K. Lee, L. Racioppi, S. Marie-kunze et al., Systems biology of vaccination for seasonal influenza in humans, Nature Immunology, vol.12, issue.8, p.100, 2011.

H. I. Nakaya, T. Hagan, S. S. Duraisingham, E. K. Lee, M. Kwissa et al., Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures, Immunity, vol.43, issue.6, p.41, 2015.

M. Newport, T. Goetghebuer, H. A. Weiss, H. Whittle, C. Siegrist et al., Genetic regulation of immune responses to vaccines in early life, Genes and Immunity, vol.5, issue.2, p.41, 2004.

C. M. Nielsen, M. J. White, C. Bottomley, C. Lusa, A. Rodríguez-galán et al., Impaired NK cell responses to pertussis and H1N1 influenza vaccine antigens in human cytomegalovirus-infected individuals, The Journal of Immunology, vol.194, issue.10, p.42, 2015.

F. Nommensen, S. Go, and D. Maclaren, Half-life of HBs antibody after hepatitis B vaccination: an aid to timing of booster vaccination, The Lancet, vol.334, issue.8667, p.59, 1989.

S. L. Nutt, P. D. Hodgkin, D. M. Tarlinton, and C. L. , The generation of antibodysecreting plasma cells, Nature Reviews Immunology, vol.15, issue.3, p.36, 2015.

D. O'connor and A. J. Pollard, Characterizing vaccine responses using host genomic and transcriptomic analysis, Clinical infectious diseases, vol.57, issue.6, p.41, 2013.

J. L. O'connor, C. J. Smith, F. C. Lampe, T. Hill, M. Gompels et al., Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression, AIDS, vol.28, issue.6, p.109, 2014.

T. J. O'dempsey, T. Mcardle, S. J. Ceesay, O. Secka, E. Demba et al., Meningococcal antibody titres in infants of women immunised with meningococcal polysaccharide vaccine during pregnancy, Archives of Disease in ChildhoodFetal and Neonatal Edition, vol.74, issue.1, p.58, 1996.

M. Odendahl, H. Mei, B. F. Hoyer, A. M. Jacobi, A. Hansen et al., Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response, Blood, vol.105, issue.4, p.58, 2005.

Y. Okamoto, D. C. Douek, R. D. Mcfarland, and R. A. Koup, Effects of exogenous interleukin-7 on human thymus function, Blood, vol.99, issue.8, p.110, 2002.

, Opportunistic Infections Project Team Of The Collaboration Of Observational HIV Epidemiological Research In Europe (COHERE) In EuroCoord et al. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE, PLOS Medicine, vol.9, issue.3

F. J. Palella, K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer et al., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, New England Journal of Medicine, vol.338, issue.13, p.108, 1998.

J. Palgen, N. Tchitchek, J. Elhmouzi-younes, S. Delandre, I. Namet et al., Prime and boost vaccination elicit a distinct innate myeloid cell immune response, Scientific reports, vol.8, issue.1, p.100, 2018.

K. A. Pape, J. J. Taylor, R. W. Maul, P. J. Gearhart, and J. M. , Different B cell populations mediate early and late memory during an endogenous immune response, Science, vol.331, issue.6021, p.36, 2011.

F. Pappalardo, M. Pennisi, F. Castiglione, and M. S. , Vaccine protocols optimization: in silico experiences, Biotechnology advances, vol.28, issue.1, p.118, 2010.

F. Pappalardo, G. Russo, F. M. Tshinanu, and M. Viceconti, silico clinical trials: concepts and early adoptions, p.169, 2018.

C. Pasin, F. Dufour, L. Villain, H. Zhang, and T. R. , Controlling IL-7 Injections in HIV-Infected Patients, Bulletin of Mathematical Biology, vol.80, issue.9, p.119, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01933170

C. Patel, J. M. Brotherton, A. Pillsbury, S. Jayasinghe, B. Donovan et al., The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?, Eurosurveillance, vol.23, issue.41, p.38, 2018.

S. Peng, A general stochastic maximum principle for optimal control problems, SIAM Journal on control and optimization, vol.28, issue.4, p.121, 1990.

A. S. Perelson, Modelling viral and immune system dynamics, Nature Reviews Immunology, vol.2, issue.1, p.44, 2002.

A. S. Perelson and R. M. Ribeiro, Modeling the within-host dynamics of HIV infection, BMC Biology, vol.11, issue.1, p.44, 2013.

A. S. Perelson, D. E. Kirschner, and R. De-boer, Dynamics of HIV infection of CD4+ T cells, Mathematical Biosciences, vol.114, issue.1, p.44, 1993.

C. Peters and J. Peters, An introduction to Ebola: the virus and the disease, ix-xvi, vol.179, p.47, 1999.
DOI : 10.1086/514322
URL : https://academic.oup.com/jid/article-pdf/179/Supplement_1/ix/11629974/179-Supplement_1-ix.pdf

S. Plotkin, History of vaccination, Proceedings of the National Academy of Sciences, vol.111, issue.34, p.37, 2014.

S. A. Plotkin, Correlates of protection induced by vaccination, Clinical and Vaccine Immunology, vol.17, issue.7, p.57, 2010.
DOI : 10.1128/cvi.00131-10
URL : https://cvi.asm.org/content/17/7/1055.full.pdf

A. J. Pollard, K. P. Perrett, and B. P. , Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines, Nature Reviews Immunology, vol.9, issue.3, p.40, 2009.
DOI : 10.1038/nri2494

L. S. Pontryagin, Mathematical theory of optimal processes. Routledge, p.117, 1987.
DOI : 10.1201/9780203749319

V. Pool, A. Tomovici, D. R. Johnson, D. P. Greenberg, and M. D. Decker, Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA, Vaccine, vol.36, issue.17, p.58, 2018.

T. M. Post, J. I. Freijer, and B. A. Ploeger, Extensions to the visual predictive check to facilitate model performance evaluation, Journal of Pharmacokinetics and Pharmacodynamics, vol.35, issue.2, p.71, 2008.

M. Prague, D. Commenges, and J. Drylewicz, Treatment Monitoring of HIV-Infected Patients based on Mechanistic Models, Biometrics, vol.68, issue.3, p.71, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01579531

M. Prague, D. Commenges, J. Guedj, J. Drylewicz, and T. R. , NIMROD : A program for inference via a normal approximation of the posterior in models with random, Computer Methods and Programs in Biomedicine, vol.111, issue.2, p.163, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00933752

M. Prague, D. Commenges, and T. R. , Dynamical models of biomarkers and clinical progression for personalized medicine: The HIV context, Advanced Drug Delivery Reviews, vol.65, issue.7, p.44, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00933761

M. Prague, C. Pasin, L. Wittkop, P. Duffau, E. Lazaro et al., In silico clinical trials for evaluation of HIV short-cycles strategies, Poster presented at: Conference on Retroviruses and Opportunistic Infections (CROI), p.169, 2018.

P. Group, A randomized, controlled trial of ZMapp for Ebola virus infection, New England Journal of Medicine, vol.375, issue.15, p.51, 2016.

F. H. Priddy, D. Brown, J. Kublin, K. Monahan, D. P. Wright et al., Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults, Clinical Infectious Diseases, vol.46, issue.11, p.38, 2008.

S. A. Prokopiou, L. Barbarroux, S. Bernard, J. Mafille, Y. Leverrier et al., Multiscale modeling of the early CD8 T-cell immune response in lymph nodes: an integrative study, Computation, vol.2, issue.4, p.43, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01074736

B. Pulendran, Systems vaccinology: probing humanity's diverse immune systems with vaccines, Proceedings of the National Academy of Sciences, vol.111, issue.34, p.100, 2014.

B. Pulendran and R. Ahmed, Translating innate immunity into immunological memory: implications for vaccine development, Cell, vol.124, issue.4, p.100, 2006.

B. Pulendran and R. Ahmed, Immunological mechanisms of vaccination, Nature Immunology, vol.12, issue.6, p.39, 2011.

B. Pulendran, S. Li, and H. I. Nakaya, Systems vaccinology. Immunity, vol.33, issue.4, p.99, 2010.

K. Puszynski, A. Gandolfi, and A. Onofrio, The role of stochastic gene switching in determining the pharmacodynamics of certain drugs: basic mechanisms, Journal of Pharmacokinetics and Pharmacodynamics, vol.43, issue.4, p.119, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01597291

T. D. Querec, R. S. Akondy, E. K. Lee, W. Cao, H. I. Nakaya et al., Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans, Nature Immunology, vol.10, issue.1, p.100, 2009.

A. Radbruch, G. Muehlinghaus, E. O. Luger, A. Inamine, K. G. Smith et al., Competence and competition: the challenge of becoming a long-lived plasma cell, Nature Reviews Immunology, vol.6, issue.10, p.58, 2006.

T. Rampling, K. Ewer, G. Bowyer, D. Wright, E. B. Imoukhuede et al., A monovalent chimpanzee adenovirus Ebola vaccine-preliminary report, New England Journal of Medicine, vol.52, p.54, 2015.

I. A. Ramshaw and A. J. Ramsay, The prime-boost strategy: exciting prospects for improved vaccination, Immunology today, vol.21, issue.4, p.40, 2000.

R. Rappuoli, C. W. Mandl, S. Black, D. Gregorio, and E. , Vaccines for the twenty-first century society, Nature Reviews Immunology, vol.11, issue.12, p.37, 2011.

R. Rappuoli and E. Siena, Will Systems Biology Deliver Its Promise and Contribute to the Development of New or Improved Vaccines? Systems Biology Views of Vaccine Innate and Adaptive Immunity. Cold Spring Harbor perspectives in biology, p.102, 2017.

A. Rechtien, L. Richert, H. Lorenzo, G. Martrus, B. Hejblum et al., Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV, Cell Reports, vol.20, issue.9, p.100, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01579246

J. A. Regules, J. H. Beigel, K. M. Paolino, J. Voell, A. R. Castellano et al., A recombinant vesicular stomatitis virus Ebola vaccine, New England Journal of Medicine, vol.376, issue.4, p.55, 2017.

R. D. Bruckers, L. Molenberghs, G. Vellinga, A. , V. Damme et al., Repeated-measures models to evaluate a hepatitis B vaccination programme, Statistics in Medicine, vol.20, issue.6, p.60, 2001.

S. Rerks-ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu et al., Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand, New England Journal of Medicine, vol.361, issue.23, p.40, 2009.

R. M. Ribeiro, H. Mohri, D. D. Ho, and A. S. Perelson, In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted, Proceedings of the National Academy of Sciences, vol.99, issue.24, p.65, 2002.

A. Rostami-hodjegan and G. T. Tucker, Simulation and prediction of in vivo drug metabolism in human populations from in vitro data, Nature Reviews Drug Discovery, vol.6, issue.2, p.168, 2007.

V. Rougeron, H. Feldmann, G. Grard, S. Becker, and L. E. , Ebola and Marburg haemorrhagic fever, Journal of Clinical Virology, vol.64, p.48, 2015.

F. Sallusto, A. Lanzavecchia, K. Araki, and A. R. , From vaccines to memory and back, Immunity, vol.33, issue.4, p.40, 2010.

A. Samson, M. Lavielle, and M. F. , The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model, Statistics in Medicine, vol.26, issue.27, p.73, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00263511

U. N. Sarwar, P. Costner, M. E. Enama, N. Berkowitz, Z. Hu et al., Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial, The Journal of Infectious Diseases, vol.211, issue.4, p.52, 2014.

M. Savy, K. Edmond, P. E. Fine, A. Hall, B. J. Hennig et al., Landscape analysis of interactions between nutrition and vaccine responses in children, The Journal of Nutrition, vol.139, issue.11, p.41, 2009.

B. Seddon, P. Tomlinson, and Z. R. , Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells, Nature Immunology, vol.4, issue.7, p.680, 2003.
DOI : 10.1038/ni946

R. A. Seder and R. Ahmed, Similarities and differences in CD4+ and CD8+ effector and memory T cell generation, Nature Immunology, vol.4, issue.9, p.36, 2003.

P. E. Seiden and F. Celada, A model for simulating cognate recognition and response in the immune system, Journal of Theoretical Biology, vol.158, issue.3, p.43, 1992.

J. C. Seidman, S. A. Richard, C. Viboud, and M. A. Miller, Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza and other respiratory viruses, vol.6, p.41, 2012.

I. Sereti, R. M. Dunham, J. Spritzler, E. Aga, M. A. Proschan et al., IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection, Blood, vol.113, issue.25, p.110, 2009.
DOI : 10.1182/blood-2008-10-186601
URL : http://www.bloodjournal.org/content/113/25/6304.full.pdf

R. L. Sheets, J. Stein, R. T. Bailer, R. A. Koup, C. Andrews et al., Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts, Journal of Immunotoxicology, vol.5, issue.3, p.98, 2008.

Y. Shen, Q. Meng, and P. Shi, Maximum principle for mean-field jump-diffusion stochastic delay differential equations and its application to finance, Automatica, vol.50, issue.6, p.121, 2014.
DOI : 10.1016/j.automatica.2014.03.021
URL : https://digital.library.adelaide.edu.au/dspace/bitstream/2440/84466/2/hdl_84466.pdf

S. S. Shen-orr and D. Furman, Variability in the immune system: of vaccine responses and immune states, Current Opinion in Immunology, vol.25, issue.4, p.41, 2013.

D. Sissoko, C. Laouenan, E. Folkesson, A. M'lebing, A. Beavogui et al., Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea, PLOS Medicine, vol.13, issue.3, p.51, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01327168

M. K. Slifka, R. Antia, J. K. Whitmire, and A. R. , Humoral immunity due to long-lived plasma cells, Immunity, vol.8, issue.3, p.58, 1998.
DOI : 10.1016/s1074-7613(00)80541-5
URL : https://doi.org/10.1016/s1074-7613(00)80541-5

S. Sridhar, A. Luedtke, E. Langevin, M. Zhu, M. Bonaparte et al., Effect of dengue serostatus on dengue vaccine safety and efficacy, New England Journal of Medicine, p.41, 2018.
DOI : 10.1056/nejmoa1800820

D. A. Stanley, A. N. Honko, C. Asiedu, J. C. Trefry, A. W. Lau-kilby et al., Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge, Nature Medicine, vol.20, issue.10, p.56, 2014.
DOI : 10.1038/nm.3702

R. F. Stengel, Mutation and control of the human immunodeficiency virus, Mathematical Biosciences, vol.213, issue.2, p.118, 2008.

K. E. Stephenson, H. Couto, and D. H. Barouch, New concepts in HIV-1 vaccine development, Current Opinion in Immunology, vol.41, p.39, 2016.
DOI : 10.1016/j.coi.2016.05.011
URL : https://doi.org/10.1016/j.coi.2016.05.011

N. J. Sullivan, J. E. Martin, B. S. Graham, and G. J. , Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule, Nature Reviews Microbiology, vol.7, issue.5, p.56, 2009.

N. J. Sullivan, L. Hensley, C. Asiedu, T. W. Geisbert, D. Stanley et al., CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates, Nature Medicine, vol.17, issue.9, p.56, 2011.
DOI : 10.1038/nm.2447

J. T. Tan, E. Dudl, E. Leroy, R. Murray, J. Sprent et al., IL-7 is critical for homeostatic proliferation and survival of naive T cells, Proceedings of the National Academy of Sciences, vol.98, issue.15, p.110, 2001.

M. D. Tapia, S. O. Sow, K. E. Lyke, F. C. Haidara, F. Diallo et al., Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, singleblind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. The Lancet infectious diseases, vol.16, p.54, 2016.

D. Tarlinton and K. Good-jacobson, Diversity among memory B cells: origin, consequences, and utility, Science, vol.341, issue.6151, p.58, 2013.

J. J. Taylor, M. K. Jenkins, and K. A. Pape, Heterogeneity in the differentiation and function of memory B cells, Trends in Immunology, vol.33, issue.12, p.37, 2012.

H. Theeten, K. Van-herck, O. Van-der-meeren, P. Crasta, P. Van-damme et al., Longterm antibody persistence after vaccination with a 2-dose Havrix?(inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions, Vaccine, vol.33, issue.42, p.60, 2015.

R. Thiébaut and C. Lewden, Epidemiology of discordant virologic and immunologic responses in HIV-1 infected patients, Medecine et maladies infectieuses, vol.35, p.109, 2005.

R. Thiébaut and S. Walker, Commentary When it is better to estimate a slope with only one point, QJM Quaterly Journal of Medicine, vol.101, issue.10, p.65, 2008.

R. Thiébaut, J. Drylewicz, M. Prague, C. Lacabaratz, S. Beq et al., Quantifying and predicting the effect of exogenous interleukin7 on CD4+ T cells in HIV-1 infection, PLOS Computational Biology, vol.10, issue.5, p.161, 0111.

R. Thiébaut, A. Jarne, J. Routy, I. Sereti, M. Fischl et al., Repeated cycles of recombinant human interleukin 7 in HIV-infected patients with low CD4 T-cell reconstitution on antiretroviral therapy: results of 2 phase II multicenter studies, Clinical Infectious Diseases, vol.62, issue.9, p.120, 2016.

A. Thorson, P. Formenty, C. Lofthouse, and N. Broutet, Systematic review of the literature on viral persistence and sexual transmission from recovered ebola survivors: evidence and recommendations, BMJ open, vol.6, issue.1, p.49, 2016.

, UNAIDS. Unaids data 2017, p.105, 2017.

T. Ura, K. Okuda, and M. Shimada, Developments in viral vector-based vaccines. Vaccines, vol.2, p.38, 2014.

P. Van-damme, S. Thoelen, M. Cramm, K. De-groote, A. Safary et al., Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence, Journal of Medical Virology, vol.44, issue.4, p.59, 1994.

A. W. Van-der-vaart, Asymptotic statistics (Cambridge series in statistical and probabilistic mathematics), p.70, 2000.

E. M. Van-leeuwen, J. Sprent, and C. D. Surh, Generation and maintenance of memory CD4+ T cells, Current Opinion in Immunology, vol.21, issue.2, p.36, 2009.

H. Van-loveren, J. Van-amsterdam, R. J. Vandebriel, T. G. Kimman, H. C. Rümke et al., Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors, Environmental health perspectives, vol.109, issue.8, p.41, 2001.

A. T. Vella, S. Dow, T. A. Potter, and J. Kappler, Cytokine-induced survival of activated T cells in vitro and in vivo, Proceedings of the National Academy of Sciences, vol.95, issue.7, p.110, 1998.

N. Venkatraman, D. Silman, P. M. Folegatti, and A. V. Hill, Vaccines against Ebola virus, Vaccine, vol.36, issue.36, p.51, 2018.

M. Viceconti, A. Henney, M. , and E. , In silico clinical trials: how computer simulation will transform the biomedical industry, International Journal of Clinical Trials, vol.3, issue.2, p.168, 2016.

E. Vidor, Evaluation of the persistence of vaccine-induced protection with human vaccines, Journal of comparative pathology, vol.142, p.60, 2010.

A. Vilajeliu, L. Ferrer, J. Munrós, A. Goncé, M. López et al., Pertussis vaccination during pregnancy: Antibody persistence in infants, Vaccine, vol.34, issue.33, p.58, 2016.

Y. Vodovotz, A. Xia, E. L. Read, J. Bassaganya-riera, D. A. Hafler et al., Solving immunology?, Trends in Immunology, vol.38, issue.2, p.171, 2017.

P. A. Volberding, S. W. Lagakos, M. A. Koch, C. Pettinelli, M. W. Myers et al., Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter, New England Journal of Medicine, vol.322, issue.14, p.108, 1990.

M. Voysey, A. J. Pollard, M. Sadarangani, and T. R. Fanshawe, Prevalence and decay of maternal pneumococcal and meningococcal antibodies: A meta-analysis of type-specific decay rates, Vaccine, vol.35, issue.43, p.58, 2017.

Y. Wang, J. Li, Y. Hu, Q. Liang, M. Wei et al., Ebola vaccines in clinical trial: the promising candidates, Human vaccines & immunotherapeutics, vol.13, issue.1, p.51, 2017.
DOI : 10.1080/21645515.2016.1225637
URL : https://www.tandfonline.com/doi/pdf/10.1080/21645515.2016.1225637?needAccess=true

E. J. Wherry and R. Ahmed, Memory CD8 T-cell differentiation during viral infection, Journal of Virology, vol.78, issue.11, p.40, 2004.
DOI : 10.1128/jvi.78.11.5535-5545.2004
URL : https://jvi.asm.org/content/jvi/78/11/5535.full.pdf

M. T. White, R. Verity, J. T. Griffin, K. P. Asante, S. Owusu-agyei et al., Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. The Lancet infectious diseases, vol.15, p.60, 2015.

, WHO. Ebola virus disease, vol.49, p.50, 2018.

, Democratic Republic of Congo. External situation report 17, 2018.

, Ebola virus disease. Democratic Republic of Congo. External situation report 3, 2018.

B. Who, Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola, 2015_ 0703TablesofEbolaDrugs.pdf?ua=1. 51 WHO. 10 facts on immunization, 2015.

, WHO. Measles: key facts, 2018.

, Correlates of vaccine-induced protection: methods and implications, 2013.

W. , Infection prevention and control guidance for care of patients in health-care settings, with focus on Ebola, interim guidance, 2016.

, Ebola virus disease, 2016.

, WHO Ebola Response Team. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections, New England Journal of Medicine, vol.371, issue.16, p.50, 2014.

G. Wiedermann, M. Kundi, F. Ambrosch, A. Safary, and E. D'hondt, Inactivated hepatitis A vaccine: long-term antibody persistence, Vaccine, vol.15, issue.6-7, p.60, 1997.

B. L. Wiens, N. R. Bohidar, J. G. Pigeon, J. Egan, W. Hurni et al., Duration of protection from clinical hepatitis A disease after vaccination with VAQTA®, Journal of Medical Virology, vol.49, issue.3, p.59, 1996.

W. B. Williams, Q. Han, and B. F. Haynes, Cross-reactivity of HIV vaccine responses and the microbiome, Current Opinion in HIV and AIDS, vol.13, issue.1, p.42, 2018.

J. N. Wilson, D. J. Nokes, and G. F. Medley, Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules, Vaccine, vol.25, issue.18, p.61, 2007.

S. Winkelmann, C. Schütte, V. Kleist, and M. , Markov control processes with rare state observation: Theory and application to treatment scheduling in HIV-1, Communications in Mathematical Sciences, vol.12, issue.5, p.119, 2014.

R. L. Winslow, I. D. Milligan, M. Voysey, K. Luhn, G. Shukarev et al., Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus AnkaraVectored Ebola Vaccines at 1 Year, JAMA, vol.317, issue.10, p.55, 2017.

G. Wong, J. S. Richardson, S. Pillet, A. Patel, X. Qiu et al., Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates, Science translational medicine, vol.4, issue.158, p.56, 2012.
DOI : 10.1126/scitranslmed.3004582
URL : http://stm.sciencemag.org/content/4/158/158ra146.full.pdf

S. Wu, Z. Liu, X. Qiu, and H. Wu, Modeling genome-wide dynamic regulatory network in mouse lungs with influenza infection using high-dimensional ordinary differential equations, PLOS ONE, vol.9, issue.5, p.102, 2014.
DOI : 10.1371/journal.pone.0095276
URL : https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0095276&type=printable

Y. Yang, Y. Xiao, and J. Wu, Pulse HIV vaccination: feasibility for virus eradication and optimal vaccination schedule, Bulletin of Mathematical Biology, vol.75, issue.5, pp.725-751, 2013.
DOI : 10.1007/s11538-013-9831-8

A. Yates, C. C. Chan, R. E. Callard, A. J. George, and J. Stark, An approach to modelling in immunology, Briefings in Bioinformatics, vol.2, issue.3, p.44, 2001.
DOI : 10.1093/bib/2.3.245
URL : https://academic.oup.com/bib/article-pdf/2/3/245/660829/245.pdf

J. Yong and X. Y. Zhou, Stochastic controls: Hamiltonian systems and HJB equations, vol.43, p.119, 1999.

M. Yotebieng, M. Maskew, and A. Van-rie, CD4 gain percentile curves for monitoring response to antiretroviral therapy in HIV-infected adults, AIDS, vol.29, issue.9, p.109, 2015.
DOI : 10.1097/qad.0000000000000649
URL : http://europepmc.org/articles/pmc4487417?pdf=render

J. Young, M. Psichogiou, L. Meyer, S. Ayayi, S. Grabar et al., CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE, PLOS Medicine, p.108, 2012.

J. Yu, V. A. Smith, P. P. Wang, A. J. Hartemink, and J. E. , Advances to bayesian network inference for generating causal networks from observational biological data, Bioinformatics, vol.20, issue.18, p.102, 2004.
DOI : 10.1093/bioinformatics/bth448
URL : https://academic.oup.com/bioinformatics/article-pdf/20/18/3594/522021/bth448.pdf

S. Zeiser, U. Franz, and V. Liebscher, Autocatalytic genetic networks modeled by piecewisedeterministic Markov processes, Journal of Mathematical Biology, vol.60, issue.2, p.164, 2010.
DOI : 10.1007/s00285-009-0264-9
URL : https://hal.archives-ouvertes.fr/hal-00470252

F. Zhu, L. Hou, J. Li, S. Wu, P. Liu et al., Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial, The Lancet, vol.385, issue.9984, p.52, 2015.

F. Zhu, A. H. Wurie, L. Hou, Q. Liang, Y. Li et al., Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial, The Lancet, vol.389, p.54, 2017.